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INTRODUCTION
The placenta is an organ that is vital to support fetal
growth and development and successful pregnancy.
Trophoblast cells from the placenta proliferate, mi-
grate, and invade the uterus in order to maintain the
development of the fetus.1 Trophoblast cells are only
found when a woman is pregnant. When there is a
Abstract
Objectives: To compare the mutant p53 expression in normal
trophoblast (N) cell culture with hydatidiform mole trophoblast
(HM) cell culture which was exposed to 17β estradiol.
Methods: An experimental study conducted at the Laboratory of
Physiology Faculty of Medicine, Brawijaya University Malang
using N cell culture and HM cell culture with 17β estradiol expo-
sure. Trophoblast cell culture of normal and hydatidiform mole was
divided in 6 groups, such as: 1. Without added 17β estradiol; 2.
Added 5 nm 17β estradiol; 3. Added 10 nm 17β estradiol; 4. Added
20 nm 17β estradiol; 5. Added 40 nm 17β estradiol; 6. Added 80 nm
17β estradiol. Then performed immunocytochemistry staining using
p53 mutant primary antibody and observed the expression of p53
mutant. Data from observations analized with the ANOVA test and
correlation test.
Results: Mutant p53 expression in N cell culture showed no sig-
nificant differences in each treatment dose of 17β estradiol (p =
0086 > 0.05). The dose at 80nm 17β estradiol showed an average of
highest mutant p53 expression on N cell culture rather than giving
the dose of 17β estradiol on 40 nm, 20 nm, 10nm and 5 nm. While
the control group showed a lowest average of mutant p53 expression
in N cell culture when compared to the treatment group which was
exposed to 17β estradiol. Mutant p53 expression in HM cell culture
showed a significant difference at each treatment dose of 17β estra-
diol (p = 0.000 < 0.05). The existence of the effect of 17β estradiol
begins when the expression of mutant p53 in HM cell culture be-
comes higher after being given treatment in the form of 17β estra-
diol on the dose of 5 nm compared with the expression of 17β es-
tradiol in the control group. Then the expression of mutant p53 in
HM cell culture is increasing when given doses of 17β estradiol at
20 nm and 40 nm. At a dose of 40 nm it shows the highest expres-
sion of mutant p53. Expression of mutant p53 in HM cell culture
decreased when given at doses 80 nm.
Conclusion: Mutant p53 expression in N cell culture exposed to
17β estradiol showed no significant difference. Expression of mu-
tant p53 in HM cell culture which was exposed to 17β estradiol
showed a significant difference. Mutant p53 expression in N and
HM cell culture which was exposed to 17β estradiol showed signifi-
cantly different, in which mutant p53 expression in N cell culture is
lower than the expression of mutant p53 in HM tissue culture.
[Indones J Obstet Gynecol 2011; 35-1: 30-5]
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Abstrak
Tujuan: Membandingkan ekspresi p53 mutant pada kultur ja-
ringan plasenta normal dengan kultur jaringan mola hidatidosa
yang dipapar dengan 17β estradiol.
Metode: Suatu studi eksperimental yang dilakukan di Laborato-
rium Fisiologi Fakultas Kedokteran Universitas Brawijaya Malang
menggunakan kultur jaringan plasenta normal dan mola hidatidosa
yang dipapar 17β estradiol, kultur jaringan plasenta normal dan
mola hidatidosa dibagi dalam 6 kelompok, yaitu: 1. tanpa ditam-
bahkan 17β estradiol; 2. ditambahkan 5 nm 17β estradiol; 3. ditam-
bahkan 10 nm 17β estradiol; 4. ditambahkan 20 nm 17β estradiol;
5. ditambahkan 40 nm 17 estradiol; 6. ditambahkan 80 nm 17β es-
tradiol. Kemudian dilakukan pengecatan imunositokimia meng-
guna-kan antibodi primer p53 mutant dan dilakukan pengamatan
eks-presi p53 mutant. Data hasil pengamatan dilakukan analisis
data dengan uji ANOVA dan uji korelasi.
Hasil: Ekspresi p53 mutant pada kultur jaringan plasenta nor-
mal yang dipapar dengan 17β estradiol tidak menunjukkan adanya
perbedaan yang signifikan. Ekspresi p53 mutant pada kultur jaring-
an mola hidatidosa yang dipapar dengan 17β estradiol menunjuk-
kan adanya perbedaan yang signifikan. Ekspresi p53 mutant pada
kultur jaringan plasenta normal dengan kultur jaringan mola hi-
datidosa yang dipapar dengan 17β estradiol menunjukkan berbeda
signifikan, di mana ekspresi p53 mutant pada kultur jaringan pla-
senta normal lebih rendah daripada ekspresi p53 mutant pada kul-
tur jaringan mola hidatidosa.
Kesimpulan: Terdapat perbedaan ekspresi p53 mutant jaringan
plasenta normal dengan mola hidatidosa.
[Maj Obstet Ginekol Indones 2011; 35-1: 30-5]
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failure in trophoblastic disease differentiation of the
placenta, a form of hydropic degeneration of the cho-
rion resemble bubbles-like chorion called hydatidi-
form mole.2
Hydatidiform mole can occur in all women in the
reproductive period, the youngest patient ever re-
ported was 12 years old and the oldest was 57 years
old. Most patients will improve after HM treated com-
pletely. However, approximately 15 - 20% will un-
dergo transformation into malignant Gestational tro-
phoblastic tumors (GTT). Gestational trophoblastic
tumor is a group of malignant diseases associated
with villous chorialis and most are preceded by hy-
datidiform mole.3
Incidence of HM in the United States is 1 : 1450
- 1 : 2000 childbirth and Japan is 3 : 2000 childbirths.
Epidemiological research in Bandung and Malang in
2002 (population-based study) showed that the inci-
dence of hydatidiform mole, respectively is 1 : 500
and 1 : 400. If in Indonesia there are estimation 22
million births per year, it will happen 44000 - 55000
hydatidiform mole cases per year. When 15% of them
become malignant, GTT will occur as many as 6600
- 8250 cases per year.4
The process of carcinogenesis HM into GTT is still
not clearly understood and there is only a few studies.
Several factors are known have role in the process of
GTT carcinogenesis, include: DNA ploidy, expression
of phospholipids, oncogenes, tumor suppressor genes,
nutrition and hormonal status.5
Tumor supressor gene is a protein that easily acti-
vated when DNA damage occurs. p53 gene is the
main tumor supressor because its function in inhibit-
ing cell cycle, differentiation, apoptosis and angio-
genesis. In malignant gestational trophoblastic tumor
or choriocarcinoma, there is p53 protein mutation that
the cell proliferation is not inhibited and the cells con-
tinue to proliferate. p53 over expression is important
in the pathogenesis of complete mole and choriocar-
cinoma and related to the aggressive nature of gesta-
tional trophoblastic disease. p53 over expression as-
sociated with p53-dependent apoptosis to modulate
excessive proliferation of trophoblast.6 p53 gene mu-
tation is important in the pathogenesis of gestational
trophoblastic tumor and its progressivity in humans.
With the polymerase chain reaction (PCR) technique,
it has been detected p53 gene mutation in 30% hyda-
tiform mole, 75% choriocarcinoma and without p53
gene mutation in normal chorionic villi.7 Other stu-
dies have shown that p53 antibodies are found mainly
in cancer patients with a specificity of 96%. Antibo-
dies are primarily associated with p53 gene missense
mutations and accumulation of p53 in the tumor. p53
gene mutations play a role in uncontrolled trophoblas-
tic proliferation and neoplastic transformation.8
Natural estrogen hormones play a role in the proc-
ess of carcinogenesis in several malignancies such as
breast cancer, endometrial cancer, liver cancer, and
several other cancer types. Estrogen receptor expres-
sion contribute to determine the process of carcino-
genesis. This is supported by the fact about the oc-
currence of excessive expression of some of these
cancers. Ethynil estradiol is a synthetic estrogen com-
monly used as a contraceptive pill that proven to play
a role in the process of GTT carcinogenesis.5 Until
now there has been no research on the effects of natu-
ral estrogen 17β estradiol in HM cells.
In general, the fertility degree of post-hydatidiform
mole has not changed. When not using contraception
they will get pregnant soon after a normal menstrual
return. Naturally, estrogen which is a female sex hor-
mone, produced by the ovaries as part of the men-
strual cycle. Estrogen synthesized in ovarian and extra
ovarian tissues. In women of childbearing age, the
secretions is from the ovaries cycle until menopause.
Aromatase activity has also been detected in muscle,
fat, and neural tissue. So, naturally, women is exposed
by the endogenous estrogen for long periods of time.9
Trophoblast cells of normal and pathological is his-
tologically same which have estrogen receptor expres-
sion.10
Several theories have been advanced the occur-
rence of malignancy and one of them is a multiple
estrogen receptor signal transduction pathway that
will cause increased proliferation and inhibits apop-
tosis of endometrial stromal cell.11 Shao proved the
occurrence of carcinogenesis in MCF-7 Human Breast
Cancer Cell-induced estrogen. Until now it is still un-
clear why and how the trophoblast cells could turn
into a malignancy, so that suspected estrogen plays a
role in the transformation of trophoblast cells.
Molar trophoblastic disease prevention efforts is
needed, but until now the pathophysiology remains
unclear and very little research has been done. To
make a mole trophoblast cell research not possible in
humans. Therefore, trophoblast cell culture medium
is required in vitro that resembles the actual condi-
tions and can be given different treatment desirely.
Research on the role of estrogen in the transformation
of trophoblast cells has not been done yet, so this
study investigates the effects of estrogen (17β estra-
diol) on the expression of p53 in tissue culture of
normal placenta and hydatidiform mole.
METHOD
This research was done experimentally between con-
trol and intervention group. Experiment was perfor-
med at the Laboratory of Physiology, Faculty of Me-
dicine, Brawijaya University Malang. Research was
conducted in July 2010. This study used tissue sam-
ples originating from hydatidiform mole after suction
curretage and normal placental tissue samples from
delivery by Caesarean section, a healthy mother does
not suffer any pain with Hb level ≥ 10, with normal
pregnancies.
The objectives of this study are to observe the ex-
pression of mutant p53 in trophoblast cells of the nor-
mal placenta tissue and HM cell culture which was
not given any treatment or which was given 5 nm, 10
nm, 20 nm, 40 nm, and 80 nm 17ß estradiol exposure
in which on each well performed up to 4 times repe-
tition, then performed staining with primary mutant
p53 antibodies. Then performed counting of 100 tro-
phoblast cells, how many trophoblast cells that ex-
press mutant p53.
In this study, the independent variable is the dose of
estrogen 17ß estradiol. While the dependent variable is
the expression of p53 mutant N and HM cell culture.
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The results tabulated and presented in the form of
tables and graphs and do statistical analysis using
SPSS 13 for windows, calculated using one-way
ANOVA, Tukey test, and correlation and regression
test. Probability considered statistically significant if
p value < 0.05 with 95% confidence interval.
Staining assessment and positive gradation were
assessed with a light microscope big field 400x, then
trophoblast cells that express mutant p53 is marked
by a brown color visualization of nucleus trophoblast
cells per 100 counted.
RESULTS
This study used normal placenta and HM cell culture
without and with administration of estrogen (17β es-
tradiol) in 5 doses (5 nm, 10 nm, 20 nm, 40 nm, 80
nm). This study objective is to see the expression of
mutant p53 using mutant p53 monoclonal antibody
after confluent cells.
The confluent cells is characterized by the cell has
been attached to the attachment site and touch each
other between cells. The distance between cells that
regular and increasingly tight, flat surface marked by
the appearance of the cell nucleus, plasma membrane,
cytoplasm and extracellular matrix, with larger cell
sizes. Staining was performed with mutant p53 mono-
clonal antibody which gives brown staining in nucleus
cell.
The color brown is a visualization of crimogen dab
(diaminobenzidine). Antibody-antigen complex mu-
tant p53 will be recognized by biotin-labeled antibo-
dies. Biotin on the secondary antibody binds with
strep avidin harse rads perixidase (sahrp) which will
visualize the brown color. Observations were carried
out using a light microscope with 400x magnification,
calculated from 100 trophoblast cells, how many are
expressing p53 mutant cells.
The hypothesis H0 is accepted when determined
by the significant value gained > alpha 0.05, while
Figure 1. Conceptual framework.
17β estradiol E2 would bind to the receptor and cause the signal
transduction that affects the cell activity. The theory of the ma-
lignancy through the estrogen receptor signal transduction path-
ways will lead to increased proliferation and inhibits apoptosis
of cells. Tumor suppressor gene is a protein that easily activated
when there is damage DNA. In gestational trophoblastic malig-
nant or Choriocarcinoma, there are mutation of p53 protein that
the cell proliferation was not inhibited, so that the cells continued
to proliferate even though the cells produced a cell with mutated
DNA and abnormal.




1 2 3 4 5 6
Control  9  8 10 11  7  9  9.0 ± SD 1.58
17β estr  5 nm 10 11  9 11  8 10  9.8 ± SD 1.30
17β estr 10 nm 11 10 12 10  9 10 10.4 ± SD 1.14
17β estr 20 nm 10 12 11 10 11 11 10.8 ± SD 0.84
17β estr 40 nm 11 12 11 12  9 11 11.0 ± SD 1.22
17β estr 80 nm 12 10 13 10 11 11 11.2 ± SD 1.30




1 2 3 4 5 6
Control 55 49 60 59 57 56 56   ± SD 4.36
17β estr  5 nm 60 62 58 59 53 58 58.4 ± SD 3.36
17β estr 10 nm 68 66 63 74 71 68 68.4 ± SD 4.28
17β estr 20 nm 64 74 82 68 67 71 71   ± SD 7.14
17β estr 40 nm 88 86 94 91 87 89 89.2 ± SD 3.27
17β estr 80 nm 81 69 80 73 70 75 74.6 ± SD 5.59







Groups 17.368  5 3.473 2.217 0.086
Within
Groups 37.600 24 1.567
Total 54.967 29







Groups 3614.800  5 722.960 30.634 0.000
Within
Groups  566.400 24  23.600
Total 4184.200 29
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H0 is rejected if the significance value obtained <al-
pha 0.05. H0 of this research is no different mutant
p53 expression in N cell culture and HM cell culture
with 17β estradiol exposure. While the H1 is the dif-
ference expression of mutant p53 in N cell culture
and HM cell culture with 17β estradiol exposure.
Based on the analysis of variance showed signifi-
cant value for HM cell culture is 0.000 (p < 0.05),
so that H0 is rejected, and it can be concluded that
there are differences in mutant p53 expression in N
cell culture and HM cell culture with 17β estradiol
exposure. While mutant p53 expression in N cell cul-
ture showed no significant differences in each treat-
ment dose of 17β estradiol (p = 0086 > 0.05).
Multiple Comparisons
With this method, multiple comparisons will be made
on the expression of mutant p53 in N cell culture with
HM cell culture between each treatment of 17β estra-
diol in various doses. So to find out the differences
of 17β estradiol in various doses on the expression of
mutant p53 in N cell culture with HM cell culture, it
can be seen from the results of Tukey test (Tukey’s
Test).
Differences mutant p53 expression in each treat-
ment dose of 17β estradiol was seen in which the N
cell culture tend to have a mutant p53 expression is
lower than the expression of mutant p53 in hydatidi-
form mole tissue culture.
Table 5. Tukey Multiple Comparison Test Table for mutant p53 expression in N cell culture.
Comparison between treatment Average of
difference
Sig. Conclusion
17β estr  5 nm –0.800 0.910 Not significantly different
17β estr 10 nm –1.400 0.503 Not significantly different
Control 17β estr 20 nm –1.800 0.243 Not significantly different
17β estr 40 nm –2.000 0.156 Not significantly different
17β estr 80 nm –2.200 0.096 Not significantly different
17β estr 10 nm –0.600 0.972 Not significantly different
17β estr 5 μg 17β estr 20 nm –1.000 0.801 Not significantly different
17β estr 40 nm –1.200 0.658 Not significantly different
17β estr 80 nm –1.400 0.503 Not significantly different
17β estr 20 nm –0.400 0.995 Not significantly different
17β estr 10 μg 17β estr 40 nm –0.600 0.972 Not significantly different
17β estr 80 nm –0.800 0.910 Not significantly different
17β estr 20 μg 17β estr 40 nm –0.200 1.000 Not significantly different
17β estr 80 nm –0.400 0.995 Not significantly different
17β estr 40 μg 17β estr 80 nm –0.200 1.000 Not significantly different
Source: Primary data are processed.
Table 6. Tukey Multiple Comparison Test Table for mutant p53 expression in HM cell culture.
Comparison between treatment Average of difference Sig. Conclusion
17β estr  5 nm – 2.400 0.968 Not significantly different
17β estr 10 nm –12.400 0.006 Significantly different
Control 17β estr 20 nm –15.000 0.001 Significantly different
17β estr 40 nm –33.200 0.000 Significantly different
17β estr 80 nm –18.600 0.000 Significantly different
17β estr 10 nm –10.000 0.035 Significantly different
17β estr 5 μg 17β estr 20 nm –12.600 0.005 Significantly different
17β estr 40 nm –30.800 0.000 Significantly different
17β estr 80 nm –16.200 0.000 Significantly different
17β estr 20 nm – 2.600 0.955 Not significantly different
17β estr 10 μg 17β estr 40 nm –20.800 0.000 Significantly different
17β estr 80 nm – 6.200 0.362 Not significantly different
17β estr 20 μg 17β estr 40 nm –18.200 0.000 Significantly different
17β estr 80 nm – 3.600 0.846 Not significantly different
17β estr 40 μg 17β estr 80 nm 14.600 0.001 Significantly different
Source: Primary data are processed.
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DISCUSSION
Differences mutant p53 expression in N cell cul-
ture which is exposed to 17β estradiol
The statistical results indicate that mutant p53 expres-
sion in N cell culture showed no significant differ-
ences in each treatment dose of 17β estradiol (p =
0086 > 0.05). Because the average difference between
each group treatments tested in this study do not differ
too much, so that statistically the differences are not
significant. From the results of this study showed that
the dose at 80 nm 17β estradiol showed an average
of highest mutant p53 expression on N cell culture
rather than giving the dose of 17β estradiol on 40 nm,
20 nm, 10 nm and 5 nm. While the control group
showed an lowest average of mutant p53 expression
in N cell culture when compared to the treatment
group which were exposed to 17β estradiol.
The absence of significant differences in the ex-
pression of mutant p53 in N cell culture which was
exposed by 17β estradiol is because under normal cir-
cumstances, low p53 protein expression in the cyto-
plasm and inactive bind to the DNA. Active p53 pro-
tein accumulates in the nucleus in response to various
cell stress.12 In addition, the N cell culture that has
no damage of DNA, will cause the concentration of
p53 protein tended to be stable. So even if exposed
to 17β estradiol, the mutant p53 expression in N cell
culture will not show any significant increase or de-
crease, so that the results of data analysis mutant p53
expression in N cell culture which are exposed with
some doses of 17β estradiol show no difference sig-
nificant. Normal p53 (wild type) was able to suppress
cell transformation caused by oncogene in culture and
can inhibit cell tumorigenic potential in animals that
were classified as suppressor gene p53. Although the
mechanism of p53 is not known for sure, there are
indications that p53 inhibit cell growth. There are se-
veral hypotheses regarding the mechanism of action:
a) p53 recognizes and then binds itself to a "specific
sequence" of DNA thought to be a certain part that
functions as a regulator, b) p53 induces the activity
of RNA polymerase, so it acts as a transcription fac-
tor.13
Differences mutant p53 expression in HM cell cul-
ture which is exposed to 17β estradiol
The statistical results indicate that mutant p53 expres-
sion in HM cell culture showed a significant differ-
ence at each treatment dose of 17β estradiol (p =
0.000 < 0.05). Therefore, the average difference bet-
ween each group treatments tested in this study differs
quite a lot, so that statistically there are significant
differences. The existence of the effect of 17β estra-
diol begins when the expression of mutant p53 in HM
cell culture become higher after being given treatment
in the form of 17β estradiol on the dose of 5 nm
compared with the expression of 17β estradiol in the
control group. Then the expression of mutant p53 in
HM cell culture is increasing when given doses of
17β estradiol at 20 nm and 40 nm. At a dose of 40
nm can show the highest expression of mutant p53.
Expression of mutant p53 in HM cell culture de-
creased when given at doses 80 nm. Therefore, based
on a descriptive according to average expression of
mutant p53 in HM cell culture, it can be said that the
treatment in the form of 17β estradiol showed a dif-
ferent effect or influence in increasing the expression
of mutant p53 in HM cell culture when compared with
control group.
The significant differences in the expression of mu-
tant p53 in HM cell culture which was exposed to
17β estradiol is because it is influenced by the pre-
sence of 17β estradiol, which causes the concentration
of mutant p53 protein can be increased in a dose of
5 nm, 10 nm, 20 nm and 40 nm, then decreased on
dose of 80 nm. This is thought to be caused by the
effect of 17β estradiol is experiencing saturation at
doses higher than 40 nm, ie at doses of 80 nm, re-
sulting in mutant p53 expression in HM cell culture
to decline. Trophoblast cells of normal and pathologi-
cal are the same histologically contained estrogen re-
ceptor expression.10 In molar trophoblast cells, there
are expressions of estrogen receptor alpha (ER-a) in
villous cytotrophoblast (CT). With western blot analy-
sis, there are estrogen receptors beta (ER-β) in the
chorionic villi (CV) limited to the syncytiotrophoblast
(ST).14 17β estradiol bind to estrogen receptors and
cause signal transduction. Oxidative metabolism of
estrogen through the cathecol, with cytochrome P-450
enzymes catalyze the oxidative metabolism of estra-
diol. Estrogen metabolites have carcinogenic proper-
ties, 3,4-quinone estrogen causes an unstable bond
with adenine and guanine in the DNA causes depuri-
nation and mutation in vitro and in vivo. Reduction
of estrogen quinon back into hydroquinon and cate-
chol led to a chance of reactive oxygen species (ROS)
formation and cause oxidative damage to lipids and
DNA due to exposure to estrogen. Exposure to vari-
ous doses of 17β estradiol on estrogen receptor satu-
ration occurs at high doses, so that the average mutant
p53 expression in HM cell culture at doses of 80 nm
are lower than those exposed to 17β estradiol at doses
of 40 nm.
Differences mutant p53 expression in N cell cul-
ture with HM cell culture which was exposed to
17β estradiol
The statistical results show that there are significant
differences in mutant p53 expression in each treat-
ment dose of 17β estradiol on N cell culture with tis-
sue culture of hydatidiform mole (p = 0.000 > 0.05).
Therefore, mutant p53 expression in each treatment
dose of 17β estradiol was seen in which the N cell
culture of mutant p53 expression tend to have lower
expression than the mutant p53 in hydatidiform mole
tissue culture. The difference between mutant p53 ex-
pression in normal placenta tissue culture with HM
cell culture tested in this study differs quite a lot, so
that statistically there are significant differences.
This is consistent with the statement that the p53
gene mutation is important in the pathogenesis of ge-
stational trophoblastic and its progressivity in hu-
mans. With the polymerase chain reaction (PCR)
technique, it has been detected p53 gene mutation in
30% hydatiform mole, 75% choriocarcinoma and
without p53 gene mutation in normal chorionic villi.7
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P53 gene mutations play a role in uncontrolled tro-
phoblastic proliferation and neoplastic transforma-
tion.8 During a stress on the cells that proliferate re-
sulting in damage to DNA, the protein will be acti-
vated. The result of activation of this protein is the
cessation of cell proliferation in G1 or G2 phase, and
apoptosis. In Gestational trophoblastic malignant or
choriocarcinoma, there are mutation of p53 protein so
the cell proliferation was not inhibited, and the cells
continued to proliferate even though the cells pro-
duced a cell with mutated DNA and abnormal.15
Yaginuma and colleagues, detects the presence of ab-
normal p53 protein in all three choriocarcinoma cell
types (SCH, JEG-3, Nuc-1). 20% protein p53 muta-
tions occur in the early phase and 80% occurred in
the final phase. The finding of p53 protein in chorio-
carcinoma cells staining indicating poor prognosis as-
sociated with this disease.16,17
While in normal circumstances, there is low p53
protein expression in the cytoplasm and inactive bin-
ding to DNA. Active p53 protein accumulates in the
nucleus in response to various cell stress. In N cell
culture which are no damage to DNA, will cause the
concentration of p53 protein tended to be stable.13
CONCLUSION
Mutant p53 expression in N cell culture exposed to
17β estradiol showed no significant difference (p >
0.05). Expression of mutant p53 in HM cell culture
which was exposed to 17β estradiol showed a signifi-
cant difference (p < 0.05), and mutant p53 expression
in N cell culture with HM cell culture which was ex-
posed to 17β estradiol showed significantly different
(p < 0.05), in which mutant p53 expression in N cell
culture is lower than the expression of mutant p53 in
HM cell culture.
SUGGESTION
Based on the conclusions and discussion of research
results, we proposed the following suggestions.
Through this research concerning the different mutant
p53 expression in N cell culture with HM cell culture
which was exposed to 17β estradiol, it is henceforth
to be developed as a basis for further research. For
subsequent studies, the results of this study can pro-
vide as preliminary studies to develop other similar
research. In addition, further research needs to be
done by extending the other variables that can in-
crease the expression of mutant p53 in hydatidiform
mole placenta tissue culture, apart from exposure to
estrogen (17β estradiol). This research is still local-
ized or in a single place that was in the General Hos-
pital dr. Saiful Anwar Malang, meaning that the re-
search results and conclusions apply only to popula-
tions, not to apply to the public, so that its scope
should be expanded again. For example, by increasing
the number of samples in the study of the wider popu-
lation, in other words increasing the number of re-
search areas, so that the conclusions of the research
results can be more representative against the ob-
served population.
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